Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Avidity Biosciences Inc (NQ: RNA )

42.56 -1.09 (-2.50%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 759,565
Open 43.86
Bid (Size) 42.00 (5)
Ask (Size) 47.00 (1)
Prev. Close 43.65
Today's Range 42.30 - 44.68
52wk Range 5.680 - 56.00
Shares Outstanding 54,462,518
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News
The company is now pivoting its technology to the cardiovascular space under a partnership with Bristol Myers Squibb. 
Via Investor's Business Daily
Assessing Avidity Biosciences: Insights From 10 Financial Analysts
Via Benzinga

Performance

YTD
+364.63%
+364.63%
1 Month
-8.88%
-8.88%
3 Month
-5.46%
-5.46%
6 Month
+43.69%
+43.69%
1 Year
+626.28%
+626.28%

More News

Read More
In-Depth Examination Of 10 Analyst Recommendations For Avidity Biosciences
Via Benzinga
Evaluating Avidity Biosciences: Insights From 10 Financial Analysts
Via Benzinga
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Unveiling 7 Analyst Insights On Avidity Biosciences
Via Benzinga
Deep Dive Into Avidity Biosciences Stock: Analyst Perspectives (10 Ratings)
Via Benzinga
The Analyst Landscape: 7 Takes On Avidity Biosciences
Via Benzinga
Why Avidity Biosciences Zoomed to a 12% Gain This Week
Via The Motley Fool
Goldman Sachs Bullish On Avidity Biosciences, Cites Scalable RNA Therapeutics Platform For Rare Diseases
Via Benzinga
Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease
Via Benzinga
This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?
Via MarketBeat
RNA Stock Earnings: Avidity Biosciences Beats EPS, Misses Revenue for Q2 2024
Via InvestorPlace
(RNA) - Analyzing Avidity Biosciences's Short Interest
Via Benzinga
Chart Of The Day: Avidity Biosciences - Something's Up?
Via Talk Markets
Expedia Posts Upbeat Earnings, Joins Akamai Technologies, Trade Desk, DXC Technology And Other Big Stocks Moving Higher On Friday
Via Benzinga
How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics
Via Investor's Business Daily
3 Stocks Doing Even Better Than Superstar Super Micro (SMCI)
Via InvestorPlace
3 Russell 2000 Growth Stocks That Could Be Worth the Risk
Via The Motley Fool
Topics Economy
Exposures Interest Rates
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing
Via Benzinga
Top Performing Industry ETFs In June: Software Leads Returns, Chipmakers Attract Most Inflows
Via Benzinga
Topics ETFs
Trading SMID Biotech Stocks In A Volatile Market
Via Talk Markets
Avidity Biosciences And CleanSpark Were Among The 10 Biggest Mid-Cap Stock Gainers Last Week (June 9-June 15): Are These In Your Portfolio?
Via Benzinga
Adobe, Avidity Biosciences And 3 Stocks To Watch Heading Into Friday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.